Mar 10, 2020, 15:41 ET
LEE'S SUMMIT, Mo., March 10, 2020/PRNewswire/ -- Viracor Eurofins, in accordance with the FDA Emergency Use Authorization Guidance, announces it will start testing specimens for Coronavirus SARS-CoV-2 RT-PCR as of March 13, 2020. The new test utilizes real-time reverse-transcriptase polymerase chain reaction (RT-PCR) technology and detects the new coronavirus (SARS-CoV-2). Viracor's qualitative Coronavirus SARS-CoV-2 RT-PCR assay will be tested on BAL, NP swab, Nasal Swab, NP Wash, and Nasal Wash specimen types. Healthcare providers can expect results the same day, 12-18 hours from receipt of specimen.
Patients with suspected cases of COVID-19 should consult with a physician regarding ways to provide a specimen for testing by Viracor. Various types of respiratory and serological specimens can be used to detect latent, acute and retrospective clinical cases associated with COVID-19.
Given the growing impact of the 2019 novel coronavirus, Viracor has been working to deliver a diagnostic solution to help combat this public health emergency. Viracor can now provide an accurate, fast test for measuring the presence of SARS-CoV-2 in patients suspected of having COVID-19.
About Viracor Eurofins
Viracor Eurofins is a leader in specialty clinical diagnostics with over 35 years and 3000 test offerings in infectious diseases, transplantation, immunology, and allergy, to aid diagnosis, treatment, and monitoring. Viracor Eurofins is committed to helping medical professionals, transplant teams, reference laboratories, and biopharmaceutical companies get results faster when it matters most. For more information about the company and the new tests, please visit https://bit.ly/2vPsab7
As a member of Eurofins Scientific, a global leader in laboratory services for specialty clinical diagnostics, discovery pharmacology and supporting clinical studies, Viracor serves many leading biopharmaceutical companies and a wide range of clinical and academic customers in the U.S.
About Eurofins - A global leader in bio-analysis
Eurofins Scientific, through its subsidiaries (hereinafter "Eurofins" or "the Group"), believes it is a global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric clinical diagnostic testing. With over 47,000 staff across a network of more than 900 independent companies in over 50 countries generally specialized by end-client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services. The Group's objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.
As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
SOURCE Viracor Eurofins